Evidence map›Paper›PMID 33658826›Full record

ArticleJournal of inflammation research2021

AST-120 Improves Cardiac Dysfunction in Acute Kidney Injury Mice via Suppression of Apoptosis and Proinflammatory NF-κB/ICAM-1 Signaling.

Wen-Ching Shen, Yu-Hsiang Chou, Li-Shian Shi, Zhi-Wei Chen, Hai-Jian Tu, Xin-Yi Lin, Guei-Jane Wang

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07182422 (Impact of Kremezin on Renal Recovery and Uremic Toxin Levels in Patients With Acute Kidney Disease), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07182422 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Impact of Kremezin on Renal Recovery and Uremic Toxin Levels in Patients With Acute Kidney Disease

TypeinterventionalSponsorChang Gung Memorial HospitalRan2025 to 2027Enrolled100ConditionsAcute Kidney Disease, Acute Kidney Injury (AKI)ArmsAST-120 (Kremezin®)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Protein lactylation in kidney diseases.Frontiers in cell and developmental biology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Gut microbiota and neonatal acute kidney injury biomarkers.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Wen-Ching ShenDepartment of Basic Medicine, Putian University, Putian City, Fujian Province, People's Republic of China.ORCID 0000-0003-0705-7467
Yu-Hsiang ChouDepartment of Internal Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan.
Li-Shian ShiDepartment of Biotechnology, National Formosa University, Yun-Lin, Taiwan.
Zhi-Wei ChenThe Affiliated Hospital of Putian University, Putian City, Fujian Province, People's Republic of China.
Hai-Jian TuThe Affiliated Hospital of Putian University, Putian City, Fujian Province, People's Republic of China.
Xin-Yi LinDepartment of Basic Medicine, Putian University, Putian City, Fujian Province, People's Republic of China.
Guei-Jane WangSchool of Medicine, Graduate Institute of Clinical Medical Science, China Medical University, Taichung, 40402, Taiwan.
Putian University · CNAsia University · TWNational Formosa University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcute kidney injury (AKI) is a devastating disorder associated with considerably high morbidity and mortality. Reports have shown that AST-120, an oral charcoal adsorbent, can reduce oxidative stress by lowering serum indoxyl sulfate levels. The effects of AST-120 and indoxyl sulfate on kidney injury and cardiac dysfunction were investigated in vivo and in vitro. PATIENTS AND

methodsPatients were tracked for enrollment upon receiving a diagnosis of AKI. Plasma was collected to determine the renal and inflammatory parameters. Renal ischemia/reperfusion (I/R) induced AKI or sham operation was performed in C57BL/6J mice. Animals were divided into sham, AKI+vehicle, and AKI+AST-120 groups. Plasma and tissues were assembled after 48 h to assess apoptotic and inflammatory responses. We also conducted human umbilical vein endothelial cell (HUVECs) and HL-1 cardiomyocyte culture studies to determine the underlying mechanisms of indoxyl sulfate's effects. Echocardiography, histopathology, biochemical indexes, ELISA, terminal dUTP nick-end labeling (TUNEL) and Western blot analysis were performed.

resultsThe cohort included 25 consecutive patients with AKI and 25 non-AKI. Plasma levels of creatinine, indoxyl sulfate, IL-1β and ICAM-1 were significantly higher in patients with AKI than in non-AKI controls. Plasma levels of blood urea nitrogen, creatinine, indoxyl sulfate, IL-1β and renal tubular injury were increased in mice after renal I/R and were decreased by AST-120 treatment. In addition, AST-120 therapy not only improved the parameters assessed by echocardiography but also substantially attenuated the elevation of plasma BNP. Oral administration of AST-120 significantly downregulated NF-κB/ICAM-1 expression and reduced cell apoptosis in both kidney and heart after renal I/R injury.

conclusionOur investigations demonstrated that AST-120 administration improves cardiac dysfunction in AKI mice via the suppression of apoptosis and proinflammatory NF-κB/ICAM-1 signaling.

Indexed as

acute kidney injuryapoptosisAST-120cardiac dysfunctioninflammationNF-κB

Identifiers

PMID33658826
PMCPMC7917393
OpenAlexW3133238808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.